Alone or in combination w/ HMG-CoA reductase inhibitors (statins) as adjunctive therapy to diet in patients w/ primary (heterozygous familial & non-familial) hypercholesterolaemia. In combination w/ fenofibrate as adjunctive therapy to diet for reduction of elevated total-C, LDL-C, Apo B & non-HDL-C in patients w/ mixed hyperlipidemia. In combination w/ statin to reduce risk of CV events (CV death, nonfatal MI & stroke, hospitalization for unstable angina or need for revascularization) in patients w/ CHD & history of acute coronary syndrome; HoFH. Reduction of elevated sitosterol & campesterol levels in patients w/ homozygous familial sitosterolaemia.
Discontinue use if myopathy is suspected. Perform LFTs prior to initiation of therapy & according to statin recommendations. Concomitant use w/ fenofibrate, cyclosporine, warfarin, another coumarin anticoagulant or fluindione. Not to be taken by patients w/ galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Not recommended in moderate or severe hepatic insufficiency. Pregnancy. Not to be used during lactation. Not recommended in childn <10 yr.
Sign Out
